Financial Data and Key Metrics Changes - The company reported GAAP revenue of $33 million for Q4 2025, an increase from $26 million in Q3 2025, primarily driven by collaboration with Gilead [35] - Cash at the end of Q4 was $1 billion, up from $841 million at the end of Q3, bolstered by a $288 million financing in November [35][36] - R&D expenses decreased to $121 million in Q4 from $141 million in Q3, while G&A expenses slightly decreased from $27 million to $26 million [35] Business Line Data and Key Metrics Changes - The confirmed overall response rate (ORR) for the 100 mg cohort of casdatifan increased from 35% to 45%, with a median progression-free survival (PFS) of 15.1 months [16][18] - The pooled analysis ORR improved from 31% to 35%, significantly higher than belzutifan's observed rates [16][18] Market Data and Key Metrics Changes - The renal cell carcinoma (RCC) market is projected to grow from over $10 billion annually today to $13 billion by 2030, with casdatifan targeting a peak sales opportunity of $5 billion in first and second-line RCC settings [24][26] - The company aims to capture a substantial share of the IO-experienced setting, which includes approximately 21,000 patients in major markets, nearly double the third-line patient population where belzutifan is approved [26] Company Strategy and Development Direction - The company is focused on establishing casdatifan as the best-in-class HIF-2 inhibitor and the new standard of care for clear cell RCC, with a fast-to-market strategy for its Phase III study, PEAK-1 [4][8] - A TKI-free regimen is being developed for frontline therapy, which is expected to improve patient quality of life and treatment outcomes [10][11] - The immunology portfolio is also being expanded, with two programs expected to enter the clinic within the next 12 months [14][30] Management's Comments on Operating Environment and Future Outlook - Management emphasized the transformative potential of 2026 for the company, with multiple data presentations and advancements in clinical programs expected [4][39] - The company is confident in its ability to fund operations until at least the second half of 2028, with a significant decrease in operating expenses anticipated for 2026 [37][38] Other Important Information - The company is leveraging its ARC-20 study to drive development strategy for casdatifan, with a focus on demonstrating its best-in-class profile [12][22] - The upcoming ASCO GU presentation is expected to provide critical data that will reinforce the differentiation of casdatifan from belzutifan [7][39] Q&A Session Summary Question: What are the benchmarks for IO therapies as the company moves away from TKI-based regimens? - Management highlighted Ipi-Nivo as a key benchmark, noting its primary progression rate of 20%-25% and PFS of around 12 months, with the goal to demonstrate meaningful improvement with casdatifan [44][46] Question: What is the status of the volrustomig plus casdatifan study? - The study was paused but continues to provide valuable data, with no primary progression observed since dose adjustments [50][51] Question: How does the company view the upcoming LITESPARK-011 data from Merck? - Management expressed optimism that positive data from Merck would validate the field and drive enrollment for PEAK-1, with confidence in outperforming Merck's combination [65][66] Question: What is the impact of potential discontinuation of STAR-121 based on futility analysis? - Management indicated minimal operational impact as the study is fully enrolled, with a decrease in expenses expected in the latter stages of the trial [81][82]

Summary of Arcus Biosciences FY Conference Call Company Overview - **Company**: Arcus Biosciences (NYSE: RCUS) - **Focus**: Development of innovative cancer therapies, particularly in the area of HIF-2 inhibitors and anti-TIGIT therapies Key Points 1. Strategic Focus on Casdatifan - Casdatifan is highlighted as a primary focus due to its ownership and strategic optionality - The drug is considered highly de-risked based on internal data and validation from belzutifan, which has a current run rate of $700 million despite being sold in late lines only - Casdatifan shows superior data compared to belzutifan across multiple efficacy measures, including progression-free survival (PFS) which is more than double that of belzutifan [2][3] 2. Upcoming Data and Studies - Anticipation for more data in 2026, particularly regarding front-line strategies and phase 3 studies - STAR-221, a phase 3 study correlating with EDGE-Gastric, is expected to read out in 2026, with 1,050 patients fully enrolled by June 2024 [5][6] - STAR-121, focusing on PD-L1 non-small cell lung cancer, will also be fully enrolled by the end of this year with 1,000 patients [6] 3. Anti-TIGIT Developments - Arcus has demonstrated differentiation between Fc-silent and Fc-enabled anti-TIGIT molecules, with promising data from the EDGE-Gastric study showing overall survival (OS) exceeding two years compared to approximately 13 months for standard treatments [4][5] - The company is optimistic about the STAR-221 results influencing the sentiment around STAR-121 [6] 4. Combination Therapies - Casdatifan is expected to provide meaningful benefits when combined with other therapies, such as cabozantinib (CABL) and anti-PD-1 agents, showing higher overall response rates compared to belzutifan combinations [9][10][11] - The combination of CAST (casdatifan) with CABL has shown a response rate of over 40% compared to 31% for belzutifan plus CABL [11] 5. Tolerability and Patient Management - CABL is favored by clinicians for its better tolerability compared to lenvatinib (Lenva), with lower incidences of common TKI-related adverse events [26][27] - The management of anemia in patients on HIF-2 therapy has been effective, with no discontinuations due to anemia reported in a cohort of 120 patients [18][19] 6. Future Directions - Arcus plans to explore additional combinations, including anti-PD-1 and bispecific therapies, to enhance treatment efficacy [30][31] - The company is focused on TKI-sparing regimens, allowing for better quality of life for patients while reserving TKIs for later stages of treatment [34] 7. Clinical Trials and Data Expectations - More mature data from the CAST plus CABL cohort is expected to be presented next year, with a focus on PFS and durability of response [21][24] - The company is also monitoring the performance of Merck's Lenva and belzutifan combinations for comparative insights [26] 8. Conclusion - Arcus Biosciences is positioned to make significant advancements in cancer treatment through its innovative therapies and strategic focus on casdatifan and anti-TIGIT developments, with several key studies and data releases anticipated in the near future [36]